Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Louie, Janice K ^a   Yang, Samuel ^a   Yen, Cynthia ^a   Acosta, Meileen ^a   Schechter, Robert ^a   Uyeki, Timothy M ^b  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; ZANAMIVIR;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; INFLUENZA A (H1N1); LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PREVALENCE; RESPIRATORY DISTRESS SYNDROME; SCHOOL CHILD; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; CYCLOPENTANES; FEMALE; GUANIDINES; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

BACTERIA (MICROORGANISMS);

EID: 84863090027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040261     Document Type: Article

References (15)

1. Louie JK, Acosta M, Winter K, Jean C, Gavali S, et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 302(17): 1896-902.
2. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362(18): 1708-19.
3. Centers for Disease Control and Prevention (CDC) (2009) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 58(15): 400-2.
4. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, et al. (2010) Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182(4): 357-63.
5. US Food and Drug Administration. Peramivir IV Questions and Answers for Health Care Providers. Available at URL http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm187980.htm (last accessed August 10, 2011).
6. Hernandez JE, Adiga R, Armstrong R, Bazan J, Bonilla H, et al. (2011) Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis. 52(6): 695-706.
7. Fry AM, Pérez A, Finelli L, (2011) Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance. JAMA 306(2): 160-2.
8. US Food and Drug Administration. Emergency Use Authorization of Peramivir IV Fact Sheet for Health Care Providers. Available:http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf. Accessed 2011 November 10.
9. Kohno S, Yen MY, Cheong HJ, Shimada J, (2011) Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus Infection. Antimicrob Agents Chemother 55(11): 5267-5276.
10. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T, (2012) Efficacy, Safety, and Pharmacokinetics of Intravenous Peramivir in Children with 2009 Pandemic A (H1N1) Influenza Virus Infection. Antimicrob Agents Chemother 56(1): 369-77.
11. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, et al. (2010) Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 7(11): e1000362.
12. Petersen E, Keld DB, Ellermann-Eriksen S, Gubbels S, Ilkjær S, et al. (2011) Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 43(6-7): 495-503.
13. Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, et al. (2010) Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 362(1): 88-9.
14. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses (2010) Available http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
15. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, et al. (2010) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59(RR-8): 1-62.